Article

jdsupra.com on 2018-08-27 19:58

Eli Lilly’s EFFIENT combination use patent found obvious

On July 13, 2018, the Federal Court dismissed Eli Lilly’s application for a prohibition order, finding that Apotex’s allegation of obviousness of ...

Related news

Polymorph Patent Not Invalid as Obvious jdsupra.com
California , United States , Switzerland
Genentech Files Patent Infringement Complaint Against Lilly Regarding Lilly’s Taltz® Product jdsupra.com
California , United States , Switzerland
Wurst Case Scenario: Sausage Tray Design Patent Found Obvious jdsupra.com
California , United States , Switzerland
A Single Prior Art Reference Can Render a Patent Obvious jdsupra.com
California , United States , Switzerland
First decision under amended PMNOC Regulations: Federal Court finds Amgen’s filgrastim patent obvious jdsupra.com
California , United States , Switzerland
KT Design Patent Primer: Patent Eligibility of Articles “Hidden in Use”jdsupra.com
California , United States , Switzerland
Use Caution When Considering Multiple IPRs Against a Single Patent jdsupra.com
California , United States , Switzerland
M$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine miamiherald.com
United States
IEli Lilly’s Tirzepatide approved in the EU days after US and UK approval invezz.com
United Kingdom , United States
MNew information on Eli Lilly’s weight-loss drug exhibits its outlook is vivid mvtelegraph.com
California , La Jolla , Lower Austria
Eli Lilly’s Profit Dented by Higher Costs wsj.com
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab Forbes
Federal Court rejects Apotex’s invalidity allegations on claims for use of abiraterone acetate in combination with prednisone jdsupra.com
California , United States , Switzerland , Canada
Global Patent Prosecution - May 2019: Strategic Use of the Patent Prosecution Highway jdsupra.com
California , United States , Switzerland
Primers and the Use of Naturally Occurring Position-Specific Signature Nucleotides are Patent Ineligible jdsupra.com
California , United States , Switzerland
Use It or Lose It: U.S. Patent and Trademark Office to Audit Certain Existing Trademark Registrations jdsupra.com
California , United States , Switzerland
The Experimental Use Exception under the Recently Amended Canadian Patent Act jdsupra.com
California , United States , Switzerland , Canada
Study reports the obvious jdsupra.com
California , United States , Switzerland
Eli Lilly’s New Compliance Chief on His Priorities6 min read wsj.com
Canada
Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern The New York Times
Veterans Affairs